

209. The evaluation of renal clearance calculations for hepatic failure patients awaiting liver transplantation

Gregory Smallwood, B.S.Ph., Pharm.D., Candace Stearns, Pharm.D., and Thomas Heffron, M.D.; Emory University School of Medicine, Atlanta, Georgia; Emory University Healthcare, Atlanta, Georgia

**Scientific Poster Presentations II****Tuesday, October 21****8:00 a.m. – 10:00 a.m.****Convention Center: Hall 2D****ENCORE PRESENTATIONS**

Abstracts marked with an “E” are Encore Presentations. Encore presentations undergo the same peer review process as all other presentations, but they may have been presented elsewhere or published in abstract form prior to the 2008 Annual Meeting. For Encore Presentations, the abstract title, authors, and original citation (if provided) are published in *Pharmacotherapy*.

FINALISTS IN ABSTRACT AWARDS COMPETITION

Abstracts marked with an “F” are finalists for the Best Poster or Best Resident and Fellow Poster. These papers were selected by a special panel of reviewers. Award winners for Best Resident and Fellow Poster and Best Poster will be announced at 9:45 a.m., Tuesday, October 21, in Hall 2D of the Kentucky International Convention Center.

ORIGINAL RESEARCH

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

Cardiovascular**19F. Phenotypic characterization of endothelial function in individuals with established atherosclerosis using two non-invasive methods.**

Almasa Bass, Pharm.D.,¹ Melissa Caughey, R.V.T.,² J. Heyward Hull III, Pharm.D., M.S.,¹ George A. Stouffer, M.D.,² Alan L. Hinderliter, M.D.,² Craig R. Lee, Pharm.D., Ph.D.¹; (1) Eshelman School of Pharmacy, UNC at Chapel Hill, Chapel Hill, NC; (2) School of Medicine, Division of Cardiology, UNC at Chapel Hill, Chapel Hill, NC

Critical Care**45E. Comparison of estimated creatinine clearance using modified diet in renal disease, Cockcroft-Gault or 24-urine equations in critically ill surgical patients.**

Anthony T. Gerlach, Pharm.D., BCPS,¹ Sheela Thomas, M.S., R.D.,¹ Joseph Dasta, M.S.,¹ Steven Steinberg, M.D.,¹ Charles Cook, M.D.,¹ Jessica Benson, Pharm.D.²; (1) The Ohio State University Medical Center, Columbus, OH; (2) The Cleveland Clinic Foundation, Columbus, OH

47. Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with thromboembolic disorders.

Robert MacLaren, Pharm.D.,¹ C.A. Bond, Pharm.D.²; (1) University of Colorado School of Pharmacy, Aurora, CO; (2) Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, TX

48E. Hypernatremic hyperosmolar state (HHS) in acute brain injury (ABI): effect on intracranial pressure.

Denise H. Rhoney, Pharm.D.,¹ Dennis Parker, Pharm.D.,¹ Xi Liu-DeRyke, Pharm.D.,¹ Lisa Forsyth, Pharm.D.,² William M. Coplin, M.D.,¹ J. Ricardo Carhuapoma, M.D.,³; (1) Wayne State University, Detroit, MI; (2) William Beaumont Hospital, Royal Oak, MI; (3) Johns Hopkins University, Baltimore, MD

49. Conversion of critically ill patients from continuous insulin infusions to subcutaneous insulin.

Kyle A. Weant, Pharm.D.,¹ Alim Ladha, M.D.,²; (1) UK HealthCare, Lexington, KY; (2) University of North Carolina at Chapel Hill, Chapel Hill, NC

50. Inpatient cardiac arrest outcomes at two major medical centers with a focus on vasopressin.

Brooke L. Baltz, Pharm.D., Lynda Tanagi, Pharm.D.; UW Medicine, Seattle, WA

51. Propylene glycol accumulation in patients receiving intravenous lorazepam infusions.

Erica L. Horinek, Pharm.D., Robert MacLaren, Pharm.D., Tyree H. Kiser, Pharm.D., Doug N. Fish, Pharm.D.; University of Colorado School of Pharmacy, Aurora, CO

52. Patients receiving chronic warfarin therapy admitted to the intensive care unit: what are the outcomes?

Gregory J. Peitz, Pharm.D.,¹ *Mark Malesker, Pharm.D.*,² Carolyn McDonald, M.D.,¹ Lee E. Morrow, M.D.,¹; (1) Creighton University Medical Center, Omaha, NE; (2) Creighton University School of Pharmacy, Omaha, NE

53F. Lipid administration in the VELOCITY trial: safety and efficacy of clevidipine butyrate intravenous emulsion in acute, severe hypertension.

Joseph F. Dasta, M.Sc., R.Ph.,¹ Jay M. Mirtallo, M.S., R.Ph.,²; (1) University of Texas, Hutto, TX; (2) The Ohio State University Medical Center, Columbus, OH

54. Clinical characteristics and outcomes of critically ill patients with carbapenem-resistant *Acinetobacter baumannii* bacteremia or pneumonia: a single-center experience.

Justin K. Rak, Pharm.D., Neil E. Ernst, Pharm.D., Eric W. Mueller, Pharm.D.; The University Hospital, Cincinnati, OH

Drug Information**55E. Lacosamide: efficacy and safety as oral adjunctive treatment in adults with partial-onset seizures.**

Steve Chung, M.D.,¹ Michael Sperling, M.D.,² Victor Biton, M.D.,³ Gregory Krauss, M.D.,⁴ Margaret Beaman, B.Sc.,⁵ David Hebert, Ph.D.,⁵ SP754 Study Group, Ph.D.⁵; (1) Barrow Neurological Institute, Phoenix, AZ; (2) Thomas Jefferson University, Philadelphia, PA; (3) Clinical Trials, Inc., Little Rock, AR; (4) John Hopkins Hospital, Baltimore, MD; (5) Schwarz Biosciences, Inc. (a member of the UCB Group), Raleigh, NC

56. Analysis of the changing incidence of non-inferiority trials.

Anne Hurley, Pharm.D., Trevor McKibbin, Pharm.D., M.Sc., BCPS, Katie Suda, Pharm.D.; University of Tennessee Health Science Center, Memphis, TN

57E. Evaluation of lacosamide in diabetic neuropathic pain trials.

Aziz Shaibani, M.D., FACP,¹ Sabine Bongardt, M.S.,² Kenneth Sommerville, M.D.,³ *Tracy Durgin, Ph.D.*,⁴; (1) Nerve and Muscle Center, Houston, TX; (2) Schwarz Biosciences GmbH (a member of the UCB Group), Monheim, Germany; (3) formerly employed at Schwarz Biosciences, Inc. (a member of the UCB Group), Raleigh, NC; (4) UCB, Inc., Smyrna, GA

Endocrinology**77. Comparison of glycemic management with the implementation of a standardized sliding-scale insulin dosing form in a community hospital.**

Crystal L. Hoffmann, Pharm.D.,¹ Tyson W.A. Brooks, Pharm.D.,² Way Huey, Pharm.D.,¹; (1) St. Luke's Hospital, Chesterfield, MO; (2) St. Luke's Hospital and St. Louis College of Pharmacy, Chesterfield, MO

78E. Use of colesevelam HCl with concomitant statin therapy in type 2 diabetes mellitus improves glycemic control and the lipid profile.

Allison B. Goldfine, M.D.,¹ Vivian A. Fonseca, M.D.,² Stacey Abby, Pharm.D.,³ Michael Jones, Ph.D.,³; (1) Joslin Diabetes Center, Boston, MA; (2) Tulane University Health Sciences Center, New Orleans, LA; (3) Daiichi Sankyo, Inc., Parsippany, NJ

79. Psychological barriers to insulin use in a veteran population.

T. Christopher Little, Pharm.D.,¹ Frank J. Svete, Pharm.D., BCPS,² Todd Lee, Pharm.D.,²; (1) Department of Veteran's Affairs, Chicago, IL; (2) Hines VA Hospital, Hines, IL

80F. Evaluation of converting patients from insulin glargine to insulin detemir.

Ginelle A. Schmidt, Pharm.D.,¹ Deanna L. McDanel, Pharm.D.,² Kathleen E. Horner, Pharm.D.,² Erin N. Newkirk, Pharm.D.,³ Karen Farris, Ph.D.,⁴; (1) The University of Iowa Hospitals and Clinics, Iowa City, IA; (2) University of Iowa Hospitals and Clinics, Iowa City, IA; (3) Froedtert & the Medical College of Wisconsin, Milwaukee, WI; (4) University of Iowa, Iowa City, IA

81. Correlation of thiazide-induced potassium changes with glucose changes.

Shawn D. Anderson, Pharm.D.,¹ Hua Feng, M.D., M.S.,¹ Rhonda M. Cooper-DeHoff, Pharm.D.,¹ *Steven M. Smith, Pharm.D.*,¹ Kent Bailey, Ph.D.,² Stephen T. Turner, M.D.,² Arlene Chapman, M.D.,³ Julie A. Johnson, Pharm.D.,¹ John G. Gums, Pharm.D.,¹; (1) University of Florida, Gainesville, FL; (2) Mayo Clinic, Rochester, MN; (3) Emory University, Atlanta, GA

82E. Improved glycemic control with real-time continuous glucose sensors in patients with type 1 diabetes.

Sam Ellis, Pharm.D.,¹ Mary Voelmlle, ANP,² Satish Garg, M.D.,² (1) University of Colorado School of Pharmacy C238-L15, Aurora, CO; (2) Barbara Davis Center for Diabetes, Aurora, CO

Geriatrics

83E. Longitudinal analysis of the relationship between concomitant anticholinergic drug use and response to donepezil in mild-to-moderate Alzheimer's disease.

Susan K. Bowles, Pharm.D., M.Sc.,¹ Swarna Weerasinghe, Ph.D.,² Sketris Ingrid, Pharm.D., MPA (HSA),² Kenneth Rockwood, M.D., FRCPC¹; (1) Dalhousie University and Centre for Health Care of the Elderly, Halifax, NS, Canada; (2) Dalhousie University, Halifax, NS, Canada

84. Medication adherence in low socioeconomic status (SES) seniors.

John T. Johnson, Pharm.D., CDE, Sally Huston, Ph.D., R.Ph., Amber Watts, Pharm.D., William Guffey, Pharm.D.; University of Georgia College of Pharmacy, Athens, GA

86. Evaluation of factors influencing fall risk in a community hospital setting.

Tracy L. Sprunger, Pharm.D.,¹ Sandra K. Lemon, Pharm.D.,² Katherine M. Malloy, Pharm.D.,² Heather Mihalek, Pharm.D.,² Christina M. Papillon, Pharm.D.²; (1) Community Health Network/Butler University, Indianapolis, IN; (2) Community Health Network, Indianapolis, IN

HIV/AIDS

95E. Low incidence of suspected abacavir hypersensitivity (ABC HSR) after implementation of HLA-B*5701 screening: results from the ARIES study.

Benjamin Young, M.D., Ph.D.,¹ Kathleen Squires, M.D.,² Parul Patel, Pharm.D.,³ Edwin DeJesus, M.D.,⁴ Nicholas C. Bellos, M.D.,⁵ Daniel S. Berger, M.D.,⁶ Daniel Murphy, M.D.,⁷ Denise H. Sutherland-Phillips, M.D.,³ Qiming Liao, Ph.D.,³ Paul G. Wannamaker, B.S.,³ Mark S. Shaefer, Pharm.D.³; (1) Division of General Internal Medicine, University of Colorado, Denver, CO; (2) Thomas Jefferson University, Philadelphia, PA; (3) GlaxoSmithKline, Research Triangle Park, NC; (4) Orlando Immunology Center, Orlando, FL; (5) Southwest Infectious Disease Associates, Dallas, TX; (6) Northstar Medical Center, Chicago, IL; (7) Clinique Medicale L'Actuel, Montreal, QC, Canada

96E. Tenofovir effect on renal function factoring in both MDRD-calculated glomerular filtration rate (GFR) and spot urine protein-to-creatinine (UPC) ratio.

Thanes Vanig, M.D.,¹ Qiming M. Liao, Ph.D.,² Belinda Ha, Ph.D.,² Carol Williams, FNP¹; (1) Spectrum Medical Group, Phoenix, AZ; (2) GlaxoSmithKline, Research Triangle Park, NC

97. Simplified maintenance therapy with ABC/3TC+ATV after ABC/3TC+ATV/RTV induction: 48 week results.

Richard Elion, M.D.,¹ Daniel S. Berger, M.D.,² Gary Richmond, M.D.,³ Michael Sension, M.D.,⁴ Edwin DeJesus, M.D.,⁵ Paul Cimoch, M.D.,⁶ Linda H. Yau, Ph.D.,⁷ Belinda Ha, Ph.D.⁷; (1) George Washington University, Washington, DC; (2) Northstar Medical Center, Chicago, IL; (3) Broward General Medical Center, Ft. Lauderdale, FL; (4) Comprehensive Care Center, Ft. Lauderdale, FL; (5) Orlando Immunology Center, Orlando, FL; (6) Center for Special Immunology, Fountain Valley, CA; (7) GlaxoSmithKline, Research Triangle Park, NC

98E. Efficacy and safety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TDF/FTC) in combination with QD lopinavir/ritonavir (LPV/r) through 48 weeks in the HEAT study.

Parul Patel, Pharm.D.,¹ Kimberly Y. Smith, M.D.,² Derek M. Fine, M.D.,³ Nicholas C. Bellos, M.D.,⁴ Louis Sloan, M.D.,⁵ Phillip Lackey, M.D.,⁶ Denise H. Sutherland-Phillips, M.D.,¹ Cindy Vavro, B.S.,¹ Qiming M. Liao, Ph.D.,¹ Mark S. Shaefer, Pharm.D.¹; (1) GlaxoSmithKline, Research Triangle Park, NC; (2) Rush University Medical Center, Chicago, IL; (3) Johns Hopkins University School of Medicine, Baltimore, MD; (4) Southwest Infectious Disease Associates, Dallas, TX; (5) North Texas Infectious Disease Consultants, Dallas, TX; (6) ID Consultants, Charlotte, NC

99. Improved triglycerides after reducing the ritonavir (RTV) boosting dose from 200mg to 100mg once daily (QD) in HIV+ patients stabilized (viral load <50c/mL) on QD RTV-boosted fosamprenavir (FPV) 1400mg + abacavir (ABC) 600mg/lamivudine (3TC) 300mg.

Dushyantha T. Jayaweera, M.D., MRCOG,¹ Gary E. Pakes, Pharm.D.²; (1) University of Miami Miller School of Medicine, Miami, FL; (2) GlaxoSmithKline, Research Triangle Park, NC

100. Foot fracture characteristics in HIV-infected patients previously treated with tenofovir (TDF)- vs non-TDF-containing HAART: results of case-series study COL109415.

Arash A. Horizon, M.D.,¹ Robert J. Joseph, DPM,² Qiming Liao, Ph.D.,³ Steven T. Ross, M.S.,³ Gary E. Pakes, Pharm.D.³; (1) Cedars-Sinai Health System, Los Angeles, CA; (2) Surgical Podiatry, Los Angeles, CA; (3) GlaxoSmithKline, Research Triangle Park, NC

In Vitro Testing of Novel Anticancer Agents

110E. Targeting Ras with false prenyl analogs.

Bojana Stevich, Pharm.D., M.S.,¹ Cynthia Mattingly, B.S.,¹ David L. DeRemer, Pharm.D.,² Peter Spielmann, Ph.D.,¹ Val Adams, Pharm.D.¹; (1) University of Kentucky, Lexington, KY; (2) Medical College of Georgia, Augusta, GA

Infectious Diseases

111. Impact of drug allergy label on a patient's clinical course.

Lisa Charneski, Pharm.D., BCPS; University of Maryland School of Pharmacy, Rockville, MD

112. Discordant minimum inhibitory concentrations (MICs) from VITEK2 and E-tests for vancomycin against methicillin-resistant *Staphylococcus aureus* (MRSA).

Scott J. Bergman, Pharm.D., BCPS,¹ Lauren Moja, Pharm.D.,² Cheryl Drake, B.S.,³ Joan Barenfanger, M.D., ABMM³; (1) Southern Illinois University Edwardsville, Box 19636, Springfield, IL; (2) Butler University, Springfield, IL; (3) Memorial Medical Center, Springfield, IL

113. Epidemiology, risk factors, and treatment of candidemia at a large academic medical center: a retrospective study.

Brett H. Heintz, Pharm.D., BCPS, Joanne C. Lee, Pharm.D., Siyuan Liu, Pharm.D., Judy Y. Kwak, Pharm.D.; University of California, Davis Medical Center, Sacramento, CA

115. Rifaximin use in *Clostridium difficile* infection (CDI).

Jamie M. Wilkerson, Pharm.D.,¹ Paul Juang, Pharm.D.²; (1) Missouri Baptist Medical Center, St. Louis, MO; (2) St. Louis College of Pharmacy, St. Louis, MO

116E. Analysis of appropriate initial antimicrobial therapy in community and healthcare-associated pneumonia and blood-stream infections.

Shawn J. Kram, Pharm.D.,¹ Garrett E. Schramm, Pharm.D.,¹ Richard A. Fricker, B.A.,¹ Bekele Afessa, M.D., FCCP²; (1) Mayo Clinic, Rochester, MN; (2) Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN

117E. Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infection (cSSSI).

Yigong Ge, M.D.,¹ Sam Liao, Ph.D.,² George H. Talbot, M.D.¹; (1) Cerexa, Inc., Alameda, CA; (2) PharMax Research, Inc., Somerset, NJ

118E. Activity of ceftaroline against *Streptococcus pneumoniae* bloodstream isolates from community-acquired pneumonia (CAP) in North America.

Yigong Ge, M.D.,¹ J. Curry,² I. Morrissey,² R. Janes²; (1) Cerexa, Inc., Alameda, CA; (2) Quotient Bioresearch Limited, Microbiology, London, UK

120F. CAS5 is required for fluconazole tolerance in *Candida albicans*.

Nathan P. Wiederhold, Pharm.D.,¹ Katherine S. Barker, Ph.D.,² Jonathan Bain, B.S.,² Vincent M. Bruno, Ph.D.,³ Aaron P. Mitchell, Ph.D.,³ P. David Rogers, Pharm.D., Ph.D.²; (1) The University of Texas at Austin College of Pharmacy and The University of Texas Health Science Center at San Antonio, San Antonio, TX; (2) University of Tennessee, Memphis, TN; (3) Columbia University, New York, NY

121. Daptomycin use in patients with sepsis.

Keith J. Christensen, Pharm.D.,¹ Scott A. McConnell, Pharm.D.,² Jack E. Brown, Pharm.D.,² Kenneth C. Lamp, Pharm.D.²; (1) Creighton University School of Pharmacy & Health Professions, Omaha, NE; (2) Cubist Pharmaceuticals, Lexington, MA

122. Plasma voriconazole levels in pediatric patients and potential application to therapeutic drug monitoring.

Maria E. Ceja, Pharm.D., Katherine Knapp, M.D., Jennifer L. Pauley, Pharm.D., Julie Richardson, Pharm.D., Kristine Crews, Pharm.D., BCPS, John C. Panetta, Ph.D., Patricia Flynn, M.D., M.S., James M. Hoffman, Pharm.D., M.S., BCPS; St. Jude Children's Research Hospital, Memphis, TN

123. A pilot study evaluating the timing of linezolid initiation after clinical failure of vancomycin in methicillin-resistant *Staphylococcus aureus* infections.

Monica Domadia, Pharm.D.,¹ Lee H. Nguyen, Pharm.D.²; (1) Loma Linda University Medical Center, Loma Linda, CA; (2) Loma Linda University, School of Pharmacy, Loma Linda, CA

124. Daptomycin treatment of urinary tract infections.

Graeme Forrest, MBBS,¹ Jason A. Crompton, Pharm.D.,² Donald S. North, Pharm.D.,² Brian J. Donovan, Pharm.D.,² Kenneth C. Lamp, Pharm.D.²; (1) University of Maryland, Baltimore, MD; (2) Cubist Pharmaceuticals, Lexington, MA

125E. Daptomycin for the treatment of *Staphylococcus aureus* bacteremia.

Kenneth C. Lamp, Pharm.D., Brian J. Donovan, Pharm.D.; Cubist Pharmaceuticals, Lexington, MA

126. Antifungal drug costs and utilization following implementation of a posaconazole prophylaxis protocol in patients with acute myelogenous leukemia.

Carrie W. Nemerovski, Pharm.D., Emily R. Mackler, Pharm.D., BCOP, Daryl D. DePestel, Pharm.D., Curtis D. Collins, Pharm.D., James G. Stevenson, Pharm.D.; University of Michigan, Ann Arbor, MI

127F. Promoting pneumococcal immunization in medical inpatients through educational efforts.

Rani P. Patel, Pharm.D., Roopali Sharma, Pharm.D.; State University of New York (SUNY) Health Sciences Center at Brooklyn's University Hospital of Brooklyn, Brooklyn, NY

128E. In vivo assessment of the activity of ceftaroline (CPT), linezolid (LZO) and vancomycin (VAN) in a rabbit osteomyelitis experimental model (OEM) due to MRSA and GISA.

Cedric Jacqueline,¹ J. Caillon,¹ G. Amador,¹ V. Le Mabeccque,¹ Yigong Ge, M.D.,² D. Biek, Ph.D.,² G. Potel,¹ A. Hamel,¹ (1) UFR Medicine, Nantes, France; (2) Cerexa, Inc., Alameda, CA

129E. Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI).

Yigong Ge, M.D.,¹ Sam Liao, Ph.D.,² Dirk A. Thye, M.D.,¹ George H. Talbot, M.D.¹; (1) Cerexa, Inc., Alameda, CA; (2) PharMax Research, Inc., Somerset, NJ

130E. In vitro activity of ceftaroline against a collection of recent gram-positive and gram-negative US isolates.

Yigong Ge, M.D.,¹ D. Biek, Ph.D.,¹ Daniel F. Sahn,² George H. Talbot, M.D.¹; (1) Cerexa, Inc., Alameda, CA; (2) Eurofins Medinet Anti-Infective Services, Herndon, VA

131E. Real-time evaluation of ceftaroline, a new cephalosporin, vs vancomycin & daptomycin in a rat *S aureus* endocarditis model using *in vivo* bioluminescent imaging.

Yan Xiong, M.D., Ph.D.,¹ Y. Li,¹ G.A. Abdelsayed,¹ D. Biek, Ph.D.,² Arnold S. Bayer¹; (1) Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; (2) Cerexa, Inc., Alameda, CA

132E. Sodium derangement among hospitalized pneumonia patients: prevalence and association to mortality and prolonged length of stay.

Andrew F. Shorr, M.D., MPH, FCCP,¹ Ying P. Tabak, Ph.D.,² Stephen G. Kurtz, M.S.,² James Spalding, Pharm.D., M.S.,³ *Vikas Gupta, Pharm.D., BCPS*²; (1) Washington Hospital Center, Washington, DC; (2) Cardinal Health Information Services, Marlborough, MA; (3) Astellas Pharma US, Inc., Deerfield, IL

133E. Assessment of vancomycin-resistant enterococcal bacteremia in a hematology and bone marrow transplant population: outcomes and risk factors associated with treatment failure.

Shawna L. Van DeKoppel, B.S., Pharm.D.,¹ Emily R. Mackler, Pharm.D.,¹ Daryl D. DePestel, Pharm.D.,¹ Peter Schlickman, Pharm.D.,²; (1) University of Michigan Health System, Ann Arbor, MI; (2) Denver Veterans Affairs Medical Center, Denver, CO

134E. Epidemiology of serum sodium correction and its impact on hospital LOS in patients admitted with pneumonia and hyponatremia.

Ying P. Tabak, Ph.D.,¹ Marya D. Zilberberg, M.D., FCCP,² Xiaowu Sun, Ph.D.,¹ James Spalding, Pharm.D.,³ R.S. Johannes, M.D., M.S.,¹ *Vikas Gupta, Pharm.D., BCPS*,¹ Andrew F. Shorr, M.D., MPH, FCCP⁴; (1) Cardinal Health Information Services, Marlborough, MA; (2) School of Public Health and Health Sciences, University of Massachusetts, Amherst, Goshen, MA; (3) Astellas Pharma US, Inc., Deerfield, IL; (4) Washington Hospital Center, Washington, DC

135. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.

Elizabeth D. Hermsen, Pharm.D., MBA,¹ *Monica Hanson, Pharm.D. Candidate*,¹ Jayashri Sankaranarayanan, M.Pharm., Ph.D.,² Julie Stoner, Ph.D.,² Marius C. Florescu, M.D.,² Mark E. Rupp, M.D.,²; (1) The Nebraska Medical Center, Omaha, NE; (2) University of Nebraska Medical Center, Omaha, NE

137. The effects of antibiotic administration on *Clostridium difficile* associated diarrhea.

Kyung sun Oh, M.S.,¹ Sukhyang Lee, Pharm.D., Ph.D.,²; (1) Graduate School of Clinical Pharmacy, Sookmyung Women's University, Seoul, South Korea; (2) Graduate School of Clinical Pharmacy, Sookmyung Women's University, Yong-San Ku, Seoul, South Korea

Informatics/Clinical Decision Support**138. Improving dyslipidemia screening and statin prescribing in diabetic patients at a community hospital using a technology-assisted pharmacist intervention.**

Peggy S. McKinnon, Pharm.D.,¹ Laura A. Noirot, B.S.,² Lisa Peters, Pharm.D.,³ Stuti Sinha, Pharm.D.,³ Richard M. Reichley, R.Ph.,² Kevin M. Heard, B.S.,² William D. Shannon, Ph.D.,⁴ Dennis A. Bouselli, Pharm.D.,³ Anne C. Goldberg, M.D.,⁴ Wm. Claiborne Dunagan, M.D.,⁴ Thomas C. Bailey, M.D.,⁴; (1) Barnes-Jewish Hospital, St. Louis, MO; (2) BJC HealthCare, St. Louis, MO; (3) Missouri Baptist Medical Center, St. Louis, MO; (4) Washington University School of Medicine, St. Louis, MO

Medication Safety**142E. Epidemiology and outcomes of patients with changes in renal function during hospitalization that may require dosage adjustment.**

Vikas Gupta, Pharm.D., BCPS,¹ Ying P. Tabak, Ph.D.,² Alisa E. Goetz, Pharm.D.,¹ Richard S. Johannes, M.D.,¹ Robert Darin, MBA¹; (1) Cardinal Health Clinical Information Services, Marlborough, MA; (2) Cardinal Health Information Services, Marlborough, MA

143E. Epidemiology and outcomes of patients treated with heparin during hospitalization.

Vikas Gupta, Pharm.D., BCPS, Juliana Hart, BSN, MPH, CPHQ, Irene Frisch, BSMT, Linda A. Hyde, RHIA, Alisa E. Goetz, Pharm.D., Richard S. Johannes, M.D., Robert Darin, MBA; Cardinal Health Clinical Information Services, Marlborough, MA

144. Impact of the implementation of a pharmacist-run discharge medication reconciliation procedure.

Christy M. Weiland, Pharm.D.,¹ Kevin King, M.D.,² Julie A. Murphy, Pharm.D.,¹; (1) St. Louis College of Pharmacy, St. Louis, MO; (2) Mercy Family Medicine, Creve Coeur, MO

145. Evaluation of a computerized physician order entry (cPOE) weight-based unfractionated heparin (UFH) protocol at Beth Israel Deaconess Medical Center (BIDMC): impact on prescribing, monitoring, safety, and achievement of therapeutic targets.

Adam B. Woolley, Pharm.D., Snehal H. Bhatt, Pharm.D., BCPS, Katherine Cunningham, Pharm.D., BCPS, M.S.; Beth Israel Deaconess Medical Center, Boston, MA

146. Pharmacist driven review and upgrade of Alaris® smart pump technology in the ICU.

Katie M. Muzevich, Pharm.D., Stacy A. Voils, Pharm.D.; Virginia Commonwealth University Health System, Richmond, VA

147. An analysis of adverse events related to peripheral intravenous catheter use in hospitalized patients.

Brian A. Hemstreet, Pharm.D., BCPS; University of Colorado Denver School of Pharmacy

Nephrology**148E. Efficacy of phosphorus binding between chewed and crushed lanthanum carbonate.**

Priscilla How, Pharm.D., Darius Mason, Pharm.D., Jose Arruda, M.D., Alan Lau, Pharm.D.; University of Illinois at Chicago, Chicago, IL

149. Outcomes associated with kidney dysfunction in cardiac surgery patients.

Judith L. Kristeller, Pharm.D.,¹ Russell Stahl, M.D.,²; (1) Wilkes University, Wilkes-Barre, PA; (2) Community Medical Center, Scranton, PA

150. Evaluation of renal dosing recommendations in FDA product labeling information of approved and marketed drugs.

*Thomas C. Dowling, Pharm.D., Ph.D.,*¹ Gary R. Matzke, Pharm.D.,² John E. Murphy, Pharm.D.,³ Gilbert J. Burckart, Pharm.D.,⁴; (1) University of Maryland, School of Pharmacy, Baltimore, MD; (2) Virginia Commonwealth University School of Pharmacy, Richmond, VA; (3) University of Arizona College of Pharmacy, Tucson, AZ; (4) Office of Clinical Pharmacology, CDER, FDA, Silver Spring, MD

152. Medication reconciliation in an outpatient hemodialysis clinic.

*Katie E. Pallotta, Pharm.D.,*¹ Darren W. Grabe, Pharm.D.,¹ Harold J. Manley, Pharm.D., BCPS,² Barbara E. Peck, R.N.³; (1) Albany College of Pharmacy, Albany, NY; (2) VillageHealth Disease Management, Albany, NY; (3) Albany Regional Kidney Center, Albany, NY

153F. Role of renal function and pharmacogenomics on mycophenolic acid pharmacokinetics in patients with glomerular diseases.

*Melanie S. Joy, Pharm.D.,*¹ Jinzhao Wang, B.S.,² Tandra Hilliard, B.S.,² Philip C. Smith, Ph.D.,³ Mary Anne Dooley, M.D., MPH,² Ronald J. Falk, M.D.²; (1) University of North Carolina, Schools of Medicine and Pharmacy, UNC Kidney Center, Chapel Hill, NC; (2) University of North Carolina, School of Medicine, Chapel Hill, NC; (3) University of North Carolina, School of Pharmacy, Chapel Hill, NC

Oncology**156. Evaluation of a change in prescribing patterns of darbepoetin alfa on red blood cell transfusion requirements in patients with chemotherapy-induced anemia.**

David M. Baribeault, B.S., BCOP; Boston Medical Center, Boston, MA

157E. Comparison of erythroid response (ER) rates to epoetin alfa (EPO) alone or in combination vs non-erythropoiesis-stimulating agents (non-ESAs) in treatment-naïve anemic MDS patients – a meta-analysis approach.

*Victor Moyo, M.D.,*¹ Patrick Lefebvre, M.A.,² Francis Vekeman, M.A.,² Mei-Sheng Duh, MPH, Sc.D.,³ Behin Yektashenas, Pharm.D.,¹ *Suneel Mundle, Ph.D.*¹; (1) Centocor Ortho Biotech Services, LLC, Bridgewater, NJ; (2) Groupe d'Analyse, Ltée., Montreal, QC, Canada; (3) Analysis Group, Inc., Boston, MA

158E. A phase II study of intravenous REOLYSIN (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.

*Scott A. Soeffe, Pharm.D.,*¹ John Sarantopoulos, M.D.,¹ Kamalesh Sankhala, M.D.,¹ Catalina C. Mita, M.D.,¹ J.J. Mahany, PA-C,¹ Tony Carmona, CCRC, CCRP,¹ Matt Coffey, Ph.D.,² George M. Gill, M.D.,² Karl Mettinger, M.D., Ph.D.,² Monica Mita, M.D.¹; (1) University of Texas Health Science Center at San Antonio Cancer Therapy & Research Center, San Antonio, TX; (2) Oncolytics Biotech, Inc., Calgary, AB, Canada

159. Pharmacokinetics of high-dose etoposide in children undergoing autologous stem cell transplantation for various solid tumors: relationship between age and clearance.

*Timothy R. McGuire, Pharm.D.,*¹ Konstantine Manouilov, Ph.D.,² Jasmine P. Davda, Ph.D.,³ Bruce Gordon, M.D.⁴; (1) UNMC College of Pharmacy, Omaha, NE; (2) Quintiles, Inc., Overland Park, KS; (3) UNMC, Omaha, NE; (4) UNMC College of Medicine, Omaha, NE

160. Impact of calcium and magnesium infusions on response rates in metastatic colorectal cancer patients treated with oxaliplatin.

Emily B. Borders, Pharm.D., Val R. Adams, Pharm.D., BCOP, FCCP; University of Kentucky, Lexington, KY

161E. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with IL-2: a phase II trial.

*Jose R. Murillo, Jr., Pharm.D.,*¹ Joan Hernandez-McClain, MPH,² Robert J. Amato, M.D.,² Valerie C. Vance, B.S.,² Jaroslav Jac, M.D.,² James P. Willis, M.D.,² Somyata X. Saxena, B.S.,² William Shingler, Ph.D.,³ Stuart Naylor, Ph.D.,³ Richard Harrop, Ph.D.³; (1) The Methodist Hospital, Houston, TX; (2) The Methodist Hospital Research Institute, Houston, TX; (3) Oxford BioMedica, Oxford, UK

Pain Management/Analgesia**164E. Pharmacokinetics of oxymorphone extended-release tablets following consumption of food or alcohol.**

William D. Fiske, Ph.D., Irma H. Benedek, Ph.D., Harry Ahdieh, Ph.D., *Nancy Alvarez, Pharm.D.;* Endo Pharmaceuticals Inc., Chadds Ford, PA

165E. Single-dose pharmacokinetic comparison of ProSorb[®] diclofenac potassium formulations.

*Keith A. Moore, Pharm.D.,*¹ Dwight Stiff, Ph.D.,² Michael Lissy, M.D.,² Stephen E. Boesing, M.S.¹; (1) Xanodyne Pharmaceuticals, Inc., Newport, KY; (2) AAIPharma Inc., Neu-Ulm, Germany

166. Complications associated with postoperative intravenous analgesia in hospitals in the United States.

*Winnie W. Nelson, Pharm.D., M.S.,*¹ Joris Diels, M.Sc.,² Shane Kavanagh, M.Sc.²; (1) Johnson & Johnson Pharmaceutical Services, Raritan, NJ; (2) Janssen Pharmaceutica, Beerse, Belgium

167E. Open-label, long-term assessment of tolerability, safety, and effectiveness of oxymorphone extended release for chronic low back pain.

*Nancy Alvarez, Pharm.D.,*¹ Martin E. Hale, M.D.,² Marvin Tark, M.D.,³ Harry Ahdieh, M.D.¹; (1) Endo Pharmaceuticals Inc., Chadds Ford, PA; (2) Gold Coast Research LLC, Weston, FL; (3) Georgia Pain Clinic, Marietta, GA

Pharmacoeconomics/Outcomes

181F. Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes.

Carleton B. Maxwell, Pharm.D.,¹ David A. Holdford, Ph.D.,² Michael A. Crouch, Pharm.D.³; (1) VCU Health Systems, Richmond, VA; (2) VCU Medical College of Virginia, Richmond, VA; (3) South University School of Pharmacy, Savannah, GA

183E. Cost-effectiveness of aliskiren added to losartan and optimal antihypertensive therapy in type-2 diabetic patients with albuminuria and hypertension.

Tom Delea, MSIA,¹ Oleg Sofrygin, M.S.,¹ *Helen Lau, M.S.*,² Veronica C. Munk, Ph.D.,³ Sean Sullivan, Ph.D.⁴; (1) PAI, Brookline, MA; (2) Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3) Novartis Pharma AG, Basel, Switzerland; (4) University of Washington, Seattle, WA

184. Persistence and compliance for patients prescribed fixed-dose valsartan/hydrochlorothiazide as compared to free combination angiotensin receptor blocker and hydrochlorothiazide.

Gregory Hess, M.D., MBA,¹ Jerrold Hill, Ph.D.,¹ Craig Plauschinat, Pharm.D., MPH,² *Homa Dastani, Ph.D.*²; (1) Surveillance Data Inc., Plymouth Meeting, PA; (2) Novartis Pharmaceuticals Corporation, East Hanover, NJ

185. A cost-efficacy analysis of infused biologic therapies in the treatment of rheumatoid arthritis using radiologic outcomes.

Boxiong Tang, M.D., Ph.D., Heidi Waters, MBA, Scott McKenzie, M.D., Catherine T. Piech, MBA; Centocor Ortho Biotech Services, LLC, Horsham, PA

186. Immunosuppressant-adherence and willingness to give time for self-management education in community-dwelling adult transplant recipients at an U.S. transplant center.

Jayashri Sankaranarayanan, M.Pharm., Ph.D., *Dean Collier, Pharm.D.*, BCPS, Anne Reisdorff, Pharm.D. Candidate; University of Nebraska Medical Center, 986045 Nebraska Medical Center, Omaha, NE

187. Cost analysis of direct thrombin inhibitor use in heparin induced thrombocytopenia at a single institution.

Shazia Raheem, Pharm.D., Andrew Eisenberger, M.D., David Diuguid, M.D., Jeffrey Jhang, M.D., Amy Dzierba, Pharm.D.; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY

Pharmacoepidemiology

188. Point prevalence of Parkinson's disease (PD) induced psychosis (PDP) in a large managed care plan.

Robert J. Holt, Pharm.D., MBA,¹ Ami R. Sklar, MPH,² George A. Goldberg, M.D., FACP,² Carolyn R. Harley, Ph.D.,² Jonathan C. Johnson, M.S. Candidate,² Theodore Darkow, Pharm.D.²; (1) Ovation Pharmaceuticals and University of Illinois, Deerfield, IL; (2) i3 Innovus, Eden Prairie, MN

189. Prevalence of cardiovascular risk factors and medication adherence among ethnic groups living in the Omaha metropolitan area.

Robyn M. Kondrack, Pharm.D., Stephanie R. Maciejewski, Pharm.D., Daniel E. Hilleman, Pharm.D., Syed M. Mohiuddin, M.D.; The Cardiac Center of Creighton University Medical Center, Omaha, NE

Pharmacogenomics/Pharmacogenetics

190E. Additive effects of $\beta 1$ 389 Arg/Gly 2c 322-325 Wt/Del adrenergic receptor genotype combinations on adjudicated hospitalizations and death in the BEST trial.

Mona Fiuzat, Pharm.D.,¹ Christopher M. O'Connor, M.D.,² Peter E. Carson, M.D.,³ Inder S. Anand, M.D., Ph.D.,⁴ Jonathan Plehn, M.D.,⁵ Stephen S. Gottlieb, M.D.,⁶ Marc A. Silver, M.D.,⁷ JoAnn Lindenfeld, M.D.,⁸ Alan Miller, M.D.,⁹ Michel White, M.D.,¹⁰ Stephen S. Liggett, M.D.,⁶ Alastair D. Robertson, Ph.D.,⁸ Michael R. Bristow, M.D., Ph.D.¹¹; (1) ARCA biopharma, Denver, CO; (2) Duke University Medical Center, Durham, NC; (3) Department of Veterans Affairs, Washington, DC; (4) Department of Veterans Affairs, Minneapolis, MN; (5) National Heart, Lung and Blood Institute, Bethesda, MD; (6) University of Maryland, School of Medicine, Baltimore, MD; (7) Advocate Christ Medical Center, Oak Lawn, IL; (8) University of Colorado Health Sciences Center, Denver, CO; (9) University of Florida, School of Medicine, Jacksonville, FL; (10) Montreal Heart Institute, Montreal, QC, Canada; (11) ARCA biopharma, University of Colorado Health Sciences Center, Denver, CO

191. Pharmacogenetic vs. clinical adjustments during warfarin initiation.

Gloria R. Grice, Pharm.D.,¹ Petra A. Lenzini, M.Sc.,² Paul E. Milligan, Pharm.D.,² Mary B. Dowd, Pharm.D.,³ Sumeet Subherwal, M.D.,² Elena Deych, M.S.,² Charles Eby, M.D.,² Cristi R. King, B.S.,² Rhonda M. Porche-Sorbet, M.S.,² Claire V. Murphy, Pharm.D.,⁴ Renee M. Marchand, Student,² Eric A. Millican, B.S.,² Robert L. Barrack, M.D.,² John C. Clohisy, M.D.,² Kathryn E. Kronquist, Ph.D.,³ Susan K. Gatchel, CCRC,² Brian F. Gage, M.D.²; (1) St. Louis College of Pharmacy, St. Louis, MO; (2) Washington University, St. Louis, MO; (3) Kaiser Permanente Colorado, Lafayette, CO; (4) Barnes-Jewish Hospital, St. Louis, MO

193E. Leukocyte expression of atherosclerosis-related genes in response to atorvastatin differs by CYP3A5 genotype.

Julio D. Duarte, Pharm.D.,¹ Gregory J. Welder, A.A., Issam Zineh, Pharm.D.; University of Florida College of Pharmacy, Gainesville, FL

194. Rapid phenotyping of ganciclovir resistance mutations from human cytomegalovirus infections in liver transplant recipients.

Gregory Smallwood, B.S.Phr., Pharm.D.,¹ Tim Barnett, Ph.D.,² Katie Casper, M.S.,² Thomas Heffron, M.D.¹; (1) Emory University School of Medicine, Atlanta, GA; (2) Children's Healthcare of Atlanta, Atlanta, GA

195. A pharmacogenetic-directed treatment strategy reduces cost of hospitalizations in patients with moderate to severe heart failure (HF) treated with bucindolol.

Bruce R. Koch II, Pharm.D.; ARCA biopharma, Inc., Denver, CO

197E. Liver X receptor alpha (LXRA) gene polymorphism associates with baseline cholesterol but not statin response in healthy volunteers.

Elvin T. Price, Pharm.D.,¹ Richard S. Schofield, M.D.,² Issam Zineh, Pharm.D.¹; (1) University of Florida College of Pharmacy Department of Pharmacy Practice and Center for Pharmacogenomics, Gainesville, FL; (2) Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL

Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery**200. Population pharmacokinetics of oritavancin.**

Christopher M. Rubino, Pharm.D., BCPS,¹ Scott A. Van Wart, M.S.,¹ Sujata M. Bhavnani, Pharm.D., M.S.,¹ Jill S. McCollam, Pharm.D.,² Paul G. Ambrose, Pharm.D., FIDSA¹; (1) ICPD/Ordway Research Institute, Albany, NY; (2) Targanta Therapeutics Corporation, Indianapolis, IN

201. Linear dose proportionality, low inter- and intrasubject variability, and safety of lisdexamfetamine dimesylate in an open-label single-dose pharmacokinetic study in healthy adult volunteers.

James Ermer, M.S.,¹ Robert Homolka, M.S.,¹ Patrick Martin, M.D.,¹ Mary Buckwalter, M.S.,¹ Jaideep Purkayastha, M.S.,¹ Benno G. Roesch, M.D.²; (1) Shire Development Inc., Wayne, PA; (2) Advanced Biomedical Research, Inc., Hackensack, NJ

202. Plasma protein binding of anidulafungin is similar to other major echinocandins.

Philip Inskeep, Ph.D., Jian Lin, M.S.; Pfizer Global Research and Development, Groton, CT

203. Pharmacokinetics of small and large molecules in a nephrotic model of glomerular disease.

Melanie S. Joy, Pharm.D.,¹ Debbie Gipson, M.D., MPH,² Howard Trachtman, M.D.³; (1) University of North Carolina, Schools of Medicine and Pharmacy, UNC Kidney Center, Chapel Hill, NC; (2) University of North Carolina, School of Medicine, Chapel Hill, NC; (3) Schneider Children's Hospital, New Hyde Park, PA

204. Evaluation of vancomycin dosing protocol for cardiothoracic surgery prophylaxis.

Mannhu N. Ton, Pharm.D., Helen S. Lee, Pharm.D., Lauri Thrupp, M.D., Jeffrey Milliken, M.D., Patria Fopiano, BSN; UC Irvine Medical Center, Orange, CA

Psychiatry**205E. A characterization of polypharmacy in an inpatient bipolar population.**

Kali M. Schulz, Pharm.D., Kevin Furmaga, Pharm.D., BCPP, G. Robert DeYoung, Pharm.D., BCPS; St. Mary's Health Care, Grand Rapids, MI

206E. Improvement in attention-deficit/hyperactivity disorder symptoms in children with lisdexamfetamine dimesylate versus extended-release mixed amphetamine salts and placebo in an analog classroom.

Frank Lopez, M.D.,¹ Ann C. Childress, M.D.,² *Stacey Curtiss, Pharm.D.*³; (1) Children's Developmental Center, Winter Park, FL; (2) Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV; (3) Shire Development Inc., Wayne, PA

Substance Abuse/Toxicology**208F. A randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking**

Larry A. Dent, Pharm.D., BCPS, Kari J. Harris, Ph.D., MPH, and Curtis W. Noonan, Ph.D.; University of Montana, Skaggs School of Pharmacy, Department of Pharmacy Practice, Missoula, Montana; University of Montana, School of Public and Community Health Sciences, Missoula, Montana; University of Montana, Skaggs School of Pharmacy, Department of Biomedical Sciences, Missoula, Montana

Transplant/Immunology**213F. Pediatric renal transplant recipients' characteristics associated with IST adherence.**

Marie A. Chisholm-Burns, Pharm.D., MPH,¹ Christina Spivey, Ph.D.,¹ Mona Zawaideh, M.D.,² Rick Rehfeld, B.A.¹; (1) The University of Arizona College of Pharmacy, Tucson, AZ; (2) The University of Arizona Department of Pediatrics, Tucson, AZ

Urology**217. Effects of silodosin, a uroselective alpha-blocker, in men with symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.**

Marc Gittelman, M.D.,¹ *Lawrence Hill, R.Ph., Pharm.D.*,² Weining Volinn, M.S.,² Gary Hoel, R.Ph., Ph.D.²; (1) South Florida Medical Research, Aventura, FL; (2) Watson Laboratories, Inc., Salt Lake City, UT

218. Long-term effects of silodosin, a uroselective alpha-blocker, in men with symptoms of benign prostatic hyperplasia.

Marc Gittelman, M.D.,¹ *Lawrence Hill, R.Ph., Pharm.D.*,² Weining Volinn, M.S.,² Gary Hoel, R.Ph., Ph.D.²; (1) South Florida Medical Research, Aventura, FL; (2) Watson Laboratories, Inc., Salt Lake City, UT

219. Pharmacokinetics of oxybutynin topical gel: effects of showering, sunscreen application, and person-to-person transference.

Kim E. Caramelli, M.S., Stephanie Stanworth, M.S., Weining Volinn, M.S., Gary Hoel, R.Ph., Ph.D.; Watson Laboratories, Inc., Salt Lake City, UT

220E. Steady-state pharmacokinetics of an investigational oxybutynin topical gel in comparison with oxybutynin transdermal system.

Kim E. Caramelli, M.S.,¹ David R. Staskin, M.D.,² Weining Volinn, M.S.¹; (1) Watson Laboratories, Inc., Salt Lake City, UT; (2) Weill Medical College of Cornell University, New York, NY

Women's Health**221F. Kansas pharmacists' knowledge, attitudes, and beliefs regarding over-the-counter emergency contraception.**

LaDonna S. Hale, Pharm.D.,¹ *Julie S. Shrack, PA-S*,¹ *Erin K. Stump, PA-S*,¹ *Gina M. Berg-Copas, Ph.D.(C)*;²; (1) Wichita State University, Wichita, KS; (2) Kansas University School of Medicine, Wichita, KS

CLINICAL PHARMACY FORUM

These abstracts describe the delivery, development, justification, or documentation of innovative clinical pharmacy services; they may be descriptive only and need not contain an evaluative component.

Community Pharmacy Practice**242F. Cost-benefit analysis of non-dispensing patient care services in an independent community pharmacy**

Erin Harris, Pharm.D., *Brenna Button-Neumann, Pharm.D.*, *Timothy Mitchell, R.Ph.*, and *Peggy G. Kuehl, Pharm.D.*; Advantage Health Care, Neosho, Missouri; University of Missouri-Kansas City School of Pharmacy, Kansas City, Missouri

Emergency Medicine**252F. Management of warfarin in a university-affiliated emergency department.**

Elena Meeker, Pharm.D., *Steven R. Kayser, Pharm.D.*, *Ellen J. Weber, M.D.*, *Cathi Dennehy, Pharm.D.*; University of California, San Francisco, San Francisco, CA

Geriatrics**253. Prospective review of all emergency department admissions for Beer's criteria drugs.**

Dan Moellentín, Pharm.D., *Benjamin Miles, Pharm.D.*; Eastern Maine Medical Center, Bangor, ME

RESEARCH INSTITUTE

The following papers based on Fellowship and Research Awards provided by the ACCP Research Institute will be presented. Full titles and authors are listed, although a complete abstract may not be available for all papers at the time of this printing.

ACCP Member Survey**334. Research Institute: ACCP Member and Frontiers Fund Donor Survey.**

Jacqueline S. Marinac, Pharm.D.; ACCP Research Institute, Lenexa, KS

Cardiovascular**335. Impact of nesiritide compared to nitroglycerin on renal function in patients with acute decompensated heart failure.****336. Renal function and neurohormonal biomarkers following nesiritide vs. nitroglycerin in acute decompensated heart failure: a prospective randomized study.**

Sheryl L. Chow, Pharm.D.,¹ *Stephen A. O'Barr, Ph.D.*,¹ *Jessica T. Peng, Pharm.D.*,² *Eric E. Chew, PA-C*,³ *Firooz Pak, M.D.*,³ *Paryus Patel, M.D.*,³ *Mark Okamoto, Pharm.D.*,⁴ *J. Thomas Heywood, M.D.*;⁵; (1) Western University of Health Sciences, Pomona, CA; (2) Western University of Health Sciences, College of Pharmacy and Centinela Freeman Regional Medical Center, Pomona, CA, Inglewood, CA; (3) Centinela Hospital, Inglewood, CA; (4) University of Hawaii at Hilo, Hilo, HI; (5) Scripps Clinic, La Jolla, CA

Infectious Diseases**337. Fluoroquinolone-resistance (FQ-R) is linked to increased cytotoxicity of *Pseudomonas aeruginosa* (PA) respiratory isolates.**

Annie Wong-Beringer, Pharm.D., *Heather M. Owens, Pharm.D., M.S.*, *Sam Lee, B.S.*; University of Southern California, Los Angeles, CA

